Betagist 24 mg (30 tablets)

  • $19.60
Sku: 185ee1a4dc08
Ingredient: Betahistine
Trade name

the International unlicensed

name Betagistin Lekarstvennaya a form
of the Tablet of 8 mg, 16 mg, 24 mg

One tablet contains
active agent – a betagistin dihydrochloride of 8 mg, 16 mg or 24 mg,
excipients: cellulose microcrystalline PH 112, Mannitolum, anhydrous citric acid, silicon dioxide colloidal (Aerosil 200), stearic acid, talc.

The description
Round tablets of white color, with a plain surface on one party and risky on another (for a dosage of 8 mg).
Round tablets of white color, biconvex, with risky on one party (for a dosage of 16 mg).
Oblong tablets of white color with risky on one party (for a dosage of 24 mg)

Pharmacotherapeutic group
of Means for elimination of dizziness.
The code of automatic telephone exchange N07CA01

the Pharmacological

Pharmacokinetics Later properties of intake of a betagistin a hydrochloride is absorbed quickly and completely.
Linking with proteins of plasma low. Betagistina a hydrochloride is quickly metabolized in a liver in an inactive main metabolite, 2-pyridylacetic acid and in dimethyl-betagistin.
It is brought to 90% through kidneys in the form of the main metabolite.
A pharmacodynamics
Betagistin is a synthetic analog of a histamine. Affects histamine H1 and H3 receptors of an inner ear and vestibular nuclei of central nervous system. Improves microcirculation and permeability of capillaries of an inner ear, increases a blood stream in basilar arteries, normalizes endolymph pressure in a labyrinth and a snail.
BETAGIST renders dose-dependent overwhelming effect on generation of peaks in neurons of lateral and medial vestibular nuclei.
BETAGIST accelerates restoration of vestibular function after unilateral neurectomy, facilitating and accelerating processes of the central vestibular compensation. This effect is carried out thanks to antagonism of H3 receptors and characterized by the raising regulation of emission and exchange of a histamine. In a combination, all these properties carry out therapeutic effect of BETAGISTA in Menyer's disease and vestibular dizziness.

- Menyer's disease/syndrome
- the symptomatic treatment of vestibular dizziness of various genesis which is followed by nausea and vomiting
- sonitus, the progressing decrease in hearing (as a part of complex therapy)

the Route of administration and doses
the Recommended initial dose makes 8-16 mg a day. The main medical doses – 24-48 mg a day.
The maximum single dose makes 24 mg.
The maximum daily dose makes 48 mg which is divided into 2-3 receptions.

Tablets on 8 mg

of the Tablet on 16 mg

of the Tablet on 24 mg

on 1-2 tablet
3 times a day

on 1/2-1 tablet
3 times a day

on 1 tablet
2 times a day

the Stable therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Long-term treatment. Duration of administration of drug is selected individually. Duration of administration of drug is defined by the attending physician.

Side effects
Often (from ³1/100 to
- a headache, drowsiness
- feeling of heat
- heartbeat
- pain in anticardium, heartburn, nausea, vomiting
- rash, urticaria, an itching, a Quincke's edema, anaphylactic reactions
- fatigue

of the Contraindication
- hypersensitivity to a betagistin to a hydrochloride and/or to any of drug components
- a pheochromocytoma
- pregnancy and the period of a lactation
- the children's and teenage age up to 18 years

Medicinal interactions
As betagistin is an analog of a histamine, simultaneous use of H1 of antagonists can cause mutual easing of effect of active agents.

Special instructions
With care to use drug at patients from a peptic ulcer of a stomach and a duodenum in the anamnesis, bronchial asthma.
Features of influence of medicine on ability of driving or potentially dangerous mechanisms
Due to the emergence of side effect in the form of fatigue the ability to reaction can be reduced that breaks ability to driving of the car and ability to operate the vehicles.

Symptoms: dryness in a mouth, nausea, vomiting, dyspepsia, an ataxy, face reddening, dizziness, the increased heartbeat, a bronchial spasm and hypostasis and after reception of very high doses can also happen convulsions.
Treatment - symptomatic (gastric lavage, use of activated carbon).

The form of release and packing
On 10 tablets place in blister strip packaging from a formatura of aluminum and printing aluminum foil.
On 3 or 6 planimetric packs together with the instruction for medical use in the state and Russian languages place in a pack cardboard with the hologram of firm – producer.

To Store storage conditions at a temperature not over 25 ºС, in the dry, protected from light place.
To store out of children's reach!

2 years
not to apply a period of storage after a period of storage.

Prescription status
According to the prescription

Republic of Kazakhstan JSC Nobel Almatinskaya Pharmatsevticheskaya Fabrika Producer,
Almaty, Shevchenko St. 162 E.

Owner of the registration certificate
of JSC Nobel Almatinskaya Pharmatsevticheskaya Fabrika
Republic of Kazakhstan
Write a review
Related Products
Sanofi-Winthrop Industrie (France)
Depakinum chrono 500 mg tablets coated 30s
Soik LLC (Russia)
Sophora + vitamins for vessels (30 capsules)
Peptogen (Russia)
SEMAX® Nasal Drops (0,1%, 1%) 3 ml Vial
Takeda (Austria)
Instenon (30 coated tablets)
Out Of Stock
Trommsdorff GmbH & Co. (Germany)
Keltican® Complex 205 mg (20 capsules)
Ferrer (Spain)
Gamalate® B6 (GB6) 60 coated tablets
Pantocalcin® (Hopantenic Acid) 250 mg, 50 tablets
Valenta Pharm (Russia)
Pantocalcin® (Hopantenic Acid) 250 mg, 50 tablets
$33.00 $43.00